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Abstract
Background: In this study, we performed a genome-wide search for effector genes bound by STOX1A, a winged helix
transcription factor recently demonstrated to be involved in late onset Alzheimer’s disease and affecting the amyloid
processing pathway.
Methodology/Principal Findings: Our results show that out of 218 genes bound by STOX1A as identified by chromatin-
immunoprecipitation followed by sequencing (ChIP-Seq), the serine/arginine-rich splicing factor 7 (SFRS7) was found to be
induced, both at the mRNA and protein levels, by STOX1A after stable transfection in glial cells. The increase in SFRS7 was
followed by an increase in the 4R/3R ratios of the microtubule-associated protein tau (MAPT) by differential exon 10 splicing.
Secondly, STOX1A also induced expression of total tau both at the mRNA and protein levels. Upregulation of total tau
expression (SFRS7-independent) and tau exon 10 splicing (SFRS7-dependent), as shown in this study to be both affected by
STOX1A, is known to have implications in neurodegeneration.
Conclusions: Our data further supports the functional importance and central role of STOX1A in neurodegeneration.
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Introduction
Storkhead box 1 (STOX1A), a transcription factor structurally
and functionally related to the forkhead family of transcription
factors, characterized by a 100 amino acid DNA-binding motif
termed the winged helix domain, was recently found to be a
susceptibility gene for pre-eclampsia [1,2], a hypertensive disorder
of pregnancy which remains a major cause of maternal and
perinatal mortality and morbidity [3]. Paradoxically, STOX1A
was also found to be functionally involved in late-onset
Alzheimer’s disease (LOAD) [4], a progressive neurodegenerative
disease of the brain which is characterized by memory loss and
impaired visiospatial skills involving elderly patients (.65 years) of
both sexes [6]. In the latter study, van Dijk and co-workers showed
that STOX1A is expressed abundantly in the brain, correlates
with the severity of late onset Alzheimer’s disease (LOAD) and
transactivates the leucine-rich repeat transmembrane 3 (LRRTM3)
gene [4]. Upregulation of the LRRTM3 gene by STOX1A leads to
increased amyloid-b precursor protein (APP) processing resulting
in higher levels of amyloid b peptide [4]. Amyloid b deposition is a
key event in the etiology of Alzheimer’s disease (AD) [5,6].
However, STOX1A transactivation of LRRTM3 could not explain
the complete STOX1A expression profile identified in the
Alzheimer brain. Given the importance of this finding in
neurodegeneration, but the lack of insight in the number and
nature of genes controlled by STOX1A in the brain, we started a
systematic search for downstream effector genes in the brain. For
this, we performed a genome-wide search for STOX1A binding
sites in the neuroblastoma cell-line SK-N-SH by chromatin-
immunoprecipitation followed by sequencing (ChIP-Seq) [7].
Subsequently, genes selected for their involvement in pathways
leading to LOAD and other neurodegenerative diseases were
explored in detail.
Results
High throughput sequencing identifies a STOX1A DNA
binding region in the promoter of SFRS7, a gene
involved in the splicing of tau exon 10
Using a genome-wide, antibody-independent approach, 218
genomic regions were found to be bound by STOX1A in SK-N-
SH cells (Dataset S1). With the algorithm Cis-regulatory Element
Annotation System (CEAS) we filtered for known functionally
important genomic regions [8]. This resulted in a top list of 115
hits associated with their corresponding regulated genes (Dataset
S2). Out of 13 genes directly positioned in known promoter
elements (Table 1), we selected the serine/arginine splicing factor
7 (SFRS7) for in-depth functional analysis given its proven effect
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on tau exon 10 splicing [9,17]. Misregulation of tau exon 10
splicing has a pathogenic role in neurodegenerative diseases
[10,11].
SFRS7 mRNA and protein expression levels are increased
in SK-N-SH cells stably transfected with STOX1A
Following independent confirmation by Q-PCR of the
STOX1A binding site in the SFRS7 promoter region (Fig. 1),
the effect of STOX1A on SFRS7 transcription and translation was
tested in SK-N-SH cells stably transfected with STOX1A or
MOCK (negative control) constructs (Fig. 2A). Both SFRS7
mRNA (Fig. 2B) and protein levels (Fig. 2C) were found to be
increased significantly and specifically upon STOX1A overex-
pression.
STOX1A effectuates changes in 4R/3R tau ratio in SK-N-
SH cells
Isoforms of the tau protein exhibit either three (3R) or four
microtubule-binding repeats (4R) depending on alternative
splicing of tau exon 10 [11]. As it has been shown that SFRS7
effects tau 4R splicing [9,17], we argued that the increased SFRS7
transcript levels cause a change in tau 4R/3R ratios. Indeed,
STOX1A leads to a significant increase in tau 4R/3R ratio
(Fig. 2D).
Secondly, endogenous total tau levels were also elevated, both at
the mRNA (Fig. 3A) and protein levels (Fig. 3B).
SFRS7-dependent tau exon 10 splicing by STOX1A is
specific for glial cells
The cell line, SK-N-SH, we used for the above in-vitro
experiments comprises a heterogeneous subpopulation of neuro-
blastic (N-type) and substrate-adherent (S-type) cells [12–15]. As
we observed a change in morphology due to clonal selection
following stable transfection (Fig. 4A vs 4B) we tested the
possibility that the phenomenon we observed was cell-specific,
i.e. either restricted to the neuroblastic (N-type) or glial (S-type)
cell. Immunostaining for disialoganglioside (GD2) (Figs. 4C, –D)
and calcyclin (Figs. 4E–F) showed the stably-transfected cells to
consist of glial cells (S-type) only (calcyclin- positive, GD2-negative)
[15]. Furthermore, no significant changes in SFRS7 expression
and tau 4R/3R ratios were found upon stable transfection of
STOX1A in the SK-N-SH N-type subclone cell- lineage SH-
SY5Y (data not shown). Given this, and to independently confirm
that the effect of STOX1A on exon 10 tau splicing via SFRS7 is
glial cell-specific, we tested U-373 MG cells as a cellular model for
glial cells. To confirm that in the STOX1A-SFRS7-tau splicing
pathway, the effect of SFRS7 on tau splicing is direct in U-373
MG cells we performed siRNA knockdown experiments against
SFRS7 in the untransfected U-373 MG cell-line and measured 3R
and 4R tau concentrations for SFRS7 siRNA treated and control
samples to calculate 4R/3R tau ratios. Significant SFRS7
knockdown was confirmed by measuring endogenous SFRS7
mRNA levels (Fig. 5A) and protein levels on western blot (Fig. 5B).
Furthermore, a significant decrease in the 4R/3R ratio for SFRS7
siRNA treated cells was seen compared to the scrambled control
(Fig. 5C) which was confirmed on western blot (Fig. 5D).
Next, we stably transfected U-373 MG cells with STOX1A to
determine the effect of STOX1A on tau exon 10 splicing via
SFRS7. First, we characterized the STOX1A expression pattern
in U-373 MG cells using immunofluorescence which showed
strong nuclear (Fig. 6A, –C) staining for STOX1A protein.
Furthermore, expression of STOX1A was confirmed on wester-
nblot (Fig. 6G).
Secondly, we determined the effect of stable STOX1A
expression on SFRS7 expression and tau exon 10 splicing.
Identical effects on SFRS7 mRNA (Fig. 7A) and protein (Fig. 7B)
levels were seen as for the SK-N-SH (S-type) cells (Fig. 2).
Furthermore, 4R/3R tau ratio’s (Fig. 7C) were significantly
increased which was confirmed on western blot (Fig. 7D) thereby
showing the effect of STOX1A on tau processing via SFRS7 in
glial cells.
Finally, as for the SK-N-SH (S-type) cells (Fig. 3), significantly
increased endogenous total tau expression, both at the mRNA
Table 1. STOX1A regulated genes identified using ChIP
sequencing.
Gene symbol Name
RAB10 ras-related GTP-binding protein
AHCY S-adenosylhomocysteine hydrolase
FSIP fibrous sheath interacting protein 1
RPL17 ribosomal protein L17
SFRS7 splicing factor, arginine/serine-rich 7
CALM2 calmodulin 2
CHST12 carbohydrate (chondroitin 4) sulfotransferase
WNT2B wingless-type MMTV integration site family
CADD45B Growth arrest and DNA-damage-inducible, beta
CLASP1 CLIP-associating protein 1
PSMF1 proteasome inhibitor subunit 1
ACTG1 actin, gamma 1 propeptide
FANK1 fibronectin type III and ankyrin repeat domains
CEAS annotation software was used to filter for regions of known functional
importance for which 13 genes were positioned directly in known promoter
regions.
doi:10.1371/journal.pone.0021994.t001
Figure 1. Validation by quantitative PCR of SFRS7 binding by
STOX1A. Results show a mean 125 fold (mean DDCt is 26,96)
enrichment for SFRS7 in STOX1A stimulated ChIP DNA compared with
their negative controls (ChIP sample vs ChIP blocked sample). Bars are
mean 6 SEM. Asterisks indicate P,0.05 (one sample t-test with
theoretical mean 0). Data were obtained from at least five independent
ChIP samples from which each DNA sample was measured in triplicate.
doi:10.1371/journal.pone.0021994.g001
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(Fig. 8A) and protein levels (Fig. 8B), was seen upon stable
STOX1A overexpression in the U-373 MG cell-line.
Discussion
Here we describe the genome-wide exploration of genomic
regions bound by STOX1A in the neuroblastoma cell-line SK-N-
SH. For this, an antibody-free chromatin immunoprecipitation
procedure was used followed by massively parallel sequencing. Of
the genes bound, the SFRS7 gene was selected for in-depth
functional analysis. We found that SFRS7-mediated splicing of tau
exon 10 is directly regulated by STOX1A in glial cells. Previously
we showed the effect of STOX1A on the amyloid pathway in
neuronal SK-N-SH cells [4]. Here we show the effect of STOX1A
on both total tau expression as well as tau processing (exon 10
splicing) in glial cells. The effect of STOX1A on tau expression
and processing additionally confirms the role of this transcription
factor in central pathways underlying neurodegeneration including
AD.
The data on tau splicing appear initially in conflict with the
observation made by Gao and co-workers who found that SFRS7
acts as a tau exon 10 splicing silencer in SK-N-SH cells thereby
decreasing the ratio of 4R/3R tau [9]. Our results show the
reverse. However, we cannot exclude that Gao and co-workers
used a mixed SK-N-SH cell population consisting of primarily N-
type and little S-type cells, while ours consisted of the S-type
subpopulation only. Possibly, in our situation, the S-type cells
transfected more easily. Therefore, transfected S-type cells were
able to overgrow the N-type cells which died from the neomycin
selection. This resulted in a cell population consisting of the S-type
subpopulation only.
Furthermore, while our results indicate that SFRS7 acts as a
splicing enhancer in the S-type of cells, the effect of STOX1A on
SFRS7 is also restricted to the S-type cells whereas we could not find
any significant changes in SFRS7 expression upon stable STOX1A
expression in the N-type subclone cell line SH-SY5Y (data not
shown). This does not exclude the role of SFRS7 acting as a tau
exon 10 splicing silencer in the neuronal S-type cells, in fact, SFRS7
has been shown to suppress tau exon 10 inclusions in the
neuroblastoma cell-line SH-SY5Y by Ding et al. [17]. Given this,
we hypothesize that both the function of SFRS7 acting as a splicing
Figure 2. STOX1A-induced SFRS7 expression is followed by increased tau splicing in SK-N-SH cells. (A) Expression of STOX1A protein
was determined with an anti-Halotag specific antibody by western blot using total cell protein extracts obtained from stable STOX1A (left lane) and
MOCK (right lane) transfected SK-N-SH cells. A specific band representing STOX1A-halotag protein was observed at its expected size of 150 kd.
Halotag protein (MOCK) was detected at its expected size of 34 kd. Westernblot image is a representative of at least 3 independent experiments. (B)
Quantitative RT-PCR data shows a mean 1.32 fold (mean DDCt is 20,4) increased mRNA expression for SFRS7. Bars are mean 6 SEM. * indicate
P,0.05 (one sample t-test with theoretical mean 0). N = 4, each sample was measured in triplicate. (C, left image) Expression of endogenous SFRS7
protein was determined with an SFRS7 specific antibody by western blot using total cell protein extracts obtained from stable STOX1A and MOCK
transfected SK-N-SH cells. An antibody specific for actin was used as a loading control. (C, right graph) Quantification of SFRS7 protein was performed
using densitometry. The ratio number of obtained band intensities for STOX1A divided by actin was compared to the ratio number of obtained band
intensities for MOCK divided by actin for 3 independent experiments. A significant increase for the STOX1A ratio number was found compared to the
MOCK ratio number. P-values were calculated using two-tailed unpaired t-test, error bars represent 6 SEM, ** indicate P,0.01. (D) Ratio numbers
were obtained by dividing endogenous 4R and 3R tau mRNA concentrations for SK-N-SH cells stably transfected with STOX1A or MOCK constructs.
Endogenous 4R and 3R mRNA concentrations were obtained as described in the material and methods section. A highly significant increase of the
4R/3R tau ratio was seen for STOX1A compared to MOCK transfected cells. P-values were calculated using two-tailed unpaired t-test, error bars
represent 6 SEM, *** indicate P,0.001. N = 4, each sample was measured in triplicate.
doi:10.1371/journal.pone.0021994.g002
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enhancer or silencer, and the effect of STOX1A on SFRS7
expression is cell-type dependent (neuronal versus glial). Therefore
our aim was to further investigate the function of STOX1A on
SFRS7 in glial cells where SFRS7 acts as an exon 10 splicing
enhancer. This theory is supported by our finding that knockdown
of SFRS7 in the U-373 MG cell-line shows an decrease in the 4R/
3R tau ratio while stable overexpression of STOX1A, which
induces SFRS7 expression, increases the 4R/3R tau ratio.
The opposite effect on tau exon 10 splicing seen after SFRS7
downregulation, as shown for glial cells in this paper, supports the cell
type dependent regulation of this splicing factor which was also
observed by Ding and co-workers [17]. Possibly, SFRS7 acts as a tau
exon 10 splicing enhancer in glial cells by binding to yet to discovered
exonic and intronic enhancers, which would not be surprising because
it has been shown that SFRS7 mainly acts as a splicing enhancer,
instead of silencer as shown by Gao and co-workers [17–20].
In LOAD, neurofibrillary tangles are one of the main hallmarks
[21]. While we previously found that in advanced stages of LOAD
(Braak 3–6), STOX1A primarily stains positive in hippocampal
neurons with neurofibrillary tangles (but also microglia) [4], the
implication in LOAD with our presented findings for STOX1A in
glial cells would therefore be possibly limited.
However, while STOX1A expression is found primarily in the
brain and dysregulation of the balance between glial 4R/3R tau
ratio by a selective increase in either 3R-tau or 4R-tau is
commonly seen in a range of diverse neurodegenerative diseases
other than LOAD, including frontotemporal dementia with
Parkinsonism linked to chromosome 17 (FTDP-17), Pick’s disease
(PD), progressive supranuclear palsy (PSP), and corticobasal
degeneration [22], further exploration of where STOX1A and/
or SFRS7 expression are found in these neurodegenerative
diseases would yield great insight of their involvement.
Interestingly, independently of SFRS7 transactivation by
STOX1A we also observed a significant increase in total tau
mRNA and protein levels in both SK-N-SH (S-type) and U-373
MG cells. While this effect is not seen after knockdown of SFRS7,
this effect is also STOX1A-dependent. As no binding site was
identified for STOX1A in the tau promoter (Dataset S1), it would
therefore be interesting to further investigate which gene, other
than tau or SFRS7 but bound by STOX1A, controls total tau
expression in glial cells.
Although we selected a single gene for functional analysis,
combined or follow-up analysis of the other genes identified will likely
generate novel results providing and permitting mechanistic insight in
pathways important for e.g. neurodegeneration. The antibody-free
ChIP procedure can be applied to other transcription factors and
cellular systems as well and is highly informative when combined with
massively parallel sequencing as done in the present paper.
In conclusion, while previous findings by van Dijk and co-
workers have shown a functional link between STOX1A and
LOAD, we here provide further evidence that STOX1A has
important functions in the pathways leading to neurodegeneration.
Materials and Methods
Cell culture and transfection
SK-N-SH human neuroblastoma cells were obtained from the
American Type Culture Collection (ATCC, Manassas, VA). All
Figure 3. STOX1A upregulates total tau RNA and protein levels in stable transfected SK-N-SH cells. (A) Quantitative RT-PCR show a
mean 3,59 fold (mean DDCt 21,84) increased mRNA expression for total tau. Bars are mean 6 SEM. P,0.05 (one sample t-test with theoretical mean
0). N = 4, each sample was measured in triplicate.(B, upper image) Expression of endogenous total tau protein was determined with a total tau
specific antibody by western blot using total cell protein extracts obtained from stable STOX1A and MOCK transfected SK-N-SH cells. An antibody
specific for actin was used as a loading control. Westernblot image is a representative of at least 3 independent experiments. (B, lower graph)
Quantification of total tau protein was performed using densitometry. The ratio number of obtained band intensities for STOX1A divided by actin was
compared to the ratio number of obtained band intensities for MOCK divided by actin for 3 independent experiments. A significant increase for the
STOX1A ratio number was found compared to the MOCK ratio number. P-values were calculated using two-tailed unpaired t-test, error bars represent
6 SEM, *** indicate P,0.001.
doi:10.1371/journal.pone.0021994.g003
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reagents for cell culture were purchased from Invitrogen Life
Technologies, Inc. (Burlington, Canada). SK-N-SH and U-373MG
cells were cultured at 37uC in a humidified atmosphere of 5% CO2
and 95% O2 in Iscove’s Modified Dulbecco’s Medium (IMDM)
supplemented with 10% fetal calf serum and 100 U/ml penicillin,
and 100 g/ml streptomycin. Cells were subcultured in medium
every 2–3 days following harvesting by trypsinization (HBSS
containing 5% trypsin). The ORF (Open Reading Frame) of the
STOX1A gene was subcloned into the Halotag pF5K neomycin
CMV Flexi vector according to the manufacturers protocol
(Promega). For transfection the calcium phosphate method was
used [16]. Briefly, at the time of transfection, cells were at 70%
confluence. By vortexing 2X HEBS (HEPES-buffered saline) with a
solution of 2.5 MCaCl2 and 20 mg of plasmid DNA a co-precipitate
of DNA and CaPO4 was allowed to form. After incubation for
30 min at room temperature, the precipitate was added to the cells
and the medium was changed after 24 h. Cells were used 48 h post-
transfection for further analysis.
For stable transfections SK-N-SH or U-373 MG cells were
transfected either with the pF5K-STOX1A or empty pF5K
constructs. Selection of positive clones was possible due to the
presence of the neomycin resistant gene present in the constructs.
Positive clones were maintained in complete IMDB medium
supplemented with 800 mg/ml G418 (Roche) until reaching
Figure 4. Stably transfected SK-N-SH cells consist of glial cells only. (A) Morphology of untransfected SK-N-SH cells or (B) stably transfected
SK-N-SH cells. The G418 (Roche) antibiotic selection procedure for selection of positive STOX1A and MOCK stable transfected cells resulted by clonal
selection in a homogeneous cell population that is composed of the glial (S-type) type. (C) Immunophenotype of untransfected SK-N-SH cells
showing intense membrane staining for GD2 but lack nuclear calcylin staining (E). No GD2 membrane staining was observed in stably transfected SK-
N-SH cells (D) while cells show high calcyclin nuclear staining (F). Green: GD2, Red: Calcyclin, Blue: DAPI.
doi:10.1371/journal.pone.0021994.g004
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Figure 5. SFRS7 acts as a tau exon 10 splicing enhancer in the glial cell-line U- 373 MG. (A) Knockdown of endogenous SFRS7 protein was
determined with quantitative RT-PCR showing a mean 9,13 fold (mean DDCt 3.19) decreased endogenous mRNA expression for SFRS7. Bars are mean
6 SEM.* indicate P,0.05 (one sample t-test with theoretical mean 0). N = 4, each sample was measured in triplicate. (B) Knockdown of endogenous
SFRS7 protein was determined with a SFRS7 specific antibody by western blot using total cell protein extracts obtained from SFRS7 siRNA and
scrambled transfected U-373 MG cells. An antibody specific for actin was used as a loading control. Westernblot image is a representative of at least 3
independent experiments. (C) Ratio numbers were obtained by dividing endogenous 4R and 3R tau mRNA concentrations from U373-MG cells
transfected with siRNA SFRS7 or scrambled siRNA. Endogenous 4R and 3R mRNA concentrations were obtained as described in the material and
methods section. A significant decrease of the 4R/3R tau ratio was seen for siRNA SFRS7 compare to scrambled siRNA transfected cells. P-values were
calculated using two-tailed unpaired t-test, error bars represent6 SEM, * indicate P,0.05. N= 4, each sample was measured in triplicate. With the use
of densitometry on obtained westernblot images (D) a similar significant decrease of the 4R/3R tau ratio was seen on a protein level (D, right graph).
Significance was calculated by combining the densitometry data from 3 independent experiments. P-values were calculated using two-tailed
unpaired t-test, error bars represent 6 SEM, * indicate P,0.05
doi:10.1371/journal.pone.0021994.g005
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confluence and subcultured every 2–3 days for about 4 weeks. A
population of positive clones was harvested for further analysis. As
confirmed with qRT-PCR (See below) using TaqMan probes
(Applied Biosystems) for STOX1A, two stable SK-N-SH cell-lines
which over-expressed STOX1A 25 and 30 fold, and 6 stable U-
373 MG cell-lines with a mean 64 fold over-expression of
STOX1A were selected. Protein expression of the STOX1A-
Halotag proteins was confirmed by western blot. Additionally,
plasmid DNA quantification using qPCR (see below) with primers
and probe specific for the constructs backbone showed similar
copy numbers in each cell-line.
Knockdown of endogenous SFRS7 was performed by trans-
fecting siRNA’s against SFRS7 and control siRNA (Santa Cruz) in
untransfected U-373 MG cells with LipofectamineTM RNAiMAX
(Invitrogen) according to the manufactures protocol. Cells were
harvested 48 hours post-transfection and RNA was isolated as
described in the Quantitative PCR and RT-PCR section.
Chromatin immunoprecipitation
Transfected cells were treated with formaldehyde to create
protein-DNA crosslinks. Cytoplasmatic lysis was performed to
reduce competition of cytoplasmatic STOX1A-Halotag proteins
against nuclear STOX1A-Halotag proteins with the Halotag resin.
Nuclear lysate was subsequently fragmented by sonication. The
nuclear lysates were split into two equal parts of which one was
treated with Halotag blocking ligand to function as a negative
control. Both the samples and controls were treated using Halotag
resin according to the Halo-ChIP system protocol in the presence
of proteinase inhibitors. After reversal of crosslinks the DNA was
purified using the Qiaquick PCR purification kit (Qiagen). The
ChIP-Seq method can be found in the additional material section
(Text S1).
Quantitative PCR and RT-PCR
Standard quantitative PCR was performed on an ABI7300
(Applied Biosystems) using probes (59-FAM 39-TAMRA labeled
SFRS7 probe 59-CGCCCAGGGCTCGA GTGAC-39) and
primers (SFRS7 forward: 59-ACGCGACATGATGACAGAC-
39, SFRS7 reversed: 59-CGCATATATAAACGCGAACC-39)
specific for the SFRS7 region obtained in the ChIP-Seq
experiments in the presence of 1M betaine and ROX reference
dye, and corrected for input using the non-intron-spanning
Figure 6. Expression analysis of STOX1A in stable transfected U-373 MG cells. (A, –C) Immunofluorescence shows primarily nuclear
staining for STOX1A-Halotag protein in stable transfected U-373 MG cells while stable MOCK-Halotag transfected U-373 MG cells shows diffuse
cytoplasmatic staining (D, –F). (G) Expression of STOX1A protein was determined with an anti-Halotag specific antibody by western blot using total
cell protein extracts obtained from stable STOX1A (left lane) and MOCK (right lane) transfected U373 cells. A specific band representing STOX1A-
halotag protein was observed at its expected size of 150 kd. Halotag (MOCK) protein was detected at its expected size of 34 kd. Westernblot image is
a representative of at least 3 independent experiments.
doi:10.1371/journal.pone.0021994.g006
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Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene
expression assay (Applied Biosystems). Input ChIP DNA was
obtained from at least five independent ChIP experiments.
RNA isolation from transfected cells was performed using the
RNeasy kit (Qiagen) including on-column DNase treatment.
Quantitative RT-PCR using gene expression assays (Applied
Biosystems) for SFRS7 and total tau was performed on an
ABI7300. In addition, transfection effiencies were corrected by
plasmid DNA quantification using the pF5 CMV-neo FlexiH
Vector backbone present in all plasmids (pF5 forward: 59-
GCTTCGAGCAGACATGATAAG-39, pF5 reversed: 59-AG-
CAATAGCATCACAAA TTTCA-39, 59-FAM 39-TAMRA la-
beled pF5 probe: 59-TGGACAAACCACAACT AGAATG-
CAGT-39). Data were obtained from at least four transfections
from which each RNA sample was measured in triplicate.
Western blot
Protein lysates from stable transfected cells were obtained by
directly scraping cells into loading Buffer including b-mercapto-
ethanol. Lysates were separated by SDS-polyacrylamide gel
electrophoresis, and electroblotted onto a PVDF-membrane. An
antibody recognizing the Halotag protein (Promega) was used in
combination with goat anti-rabbit horseradish peroxidase-conju-
gated secondary antibody (DAKO). To detect endogenous levels
of SFRS7 and tau, SFRS7 antibody (9G8, Santa Cruz) or total tau
antibody (Abcam) was used in combination with donkey anti-goat
IgG horseradish peroxidase-conjugated secondary antibody (Santa
Cruz) and goat anti-rabbit horseradish peroxidase-conjugated
secondary antibody (DAKO), respectively. Mouse monoclonal
antibodies specific for the tau 3R (RD3, clone 8E6/C11) or 4R
(RD4, clone 1E1/A6) splice variants were obtained from Millipore
Figure 7. Tau exon 10 splicing is increased upon stable STOX1A overexpression via SFRS7 in U-373 MG cells. (A) Quantitative RT-PCR
shows a mean 1,24 fold (mean DDCt is 20,306) increased mRNA expression for SFRS7. Bars are mean 6 SEM. * indicate P,0.05 (one sample t-test
with theoretical mean 0). N = 4, each sample was measured in triplicate. (B) Expression of endogenous SFRS7 protein was determined with a SFRS7
specific antibody by western blot using total cell protein extracts obtained from stable STOX1A and MOCK transfected U-373 MG cells. Westernblot
image is a representative of at least 3 independent experiments. (C) Ratio numbers were obtained by dividing endogenous 4R and 3R tau mRNA
concentrations for U373-MG cells stably transfected with STOX1A or MOCK constructs. Endogenous 4R and 3R mRNA concentrations were obtained
as described in the material and methods section. A highly significant increase of the 4R/3R tau ratio was seen for STOX1A compare to MOCK
transfected cells. P-values were calculated using two-tailed unpaired t-test, error bars represent 6 SEM, *** indicate P,0.001. N = 4, each sample was
measured in triplicate. With the use of densitometry on obtained westernblot images (D) a similar significant decrease of the 4R/3R tau ratio was seen
on a protein level. Significance was calculated by combining the densitometry data from 3 independent experiments. P-values were calculated using
two-tailed unpaired t-test, error bars represent 6 SEM, * indicate P,0.05
doi:10.1371/journal.pone.0021994.g007
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and used in combination with goat anti-mouse horseradish
peroxidase-conjugated secondary antibody (DAKO). Endogenous
actin used for loading controls was detected with mouse
monoclonal anti-actin antibody (Sigma Aldrich) used in combina-
tion with goat anti-mouse horseradish peroxidase-conjugated
secondary antibody (DAKO). Protein bands were detected by an
enhanced-chemiluminescence assay (GE Healthcare) on a
LAS3000.
Immunofluorescence
For immunofluorescence, untransfected and stable transfected
SK-N-SH cells were grown on glass coverslips. Coverslips were
fixed in 4% (PFA) paraformaldehyde for 15 min at room
temperature. After fixation, coverslips were rinsed in PBS, 0.1%
Triton X-100 and incubated with 1% Triton X-100 in PBS for
15 min at room temperature for permeabilization. Coverslips were
washed in wash buffer (PBS, 0.1% Triton X-100, 2% BSA (Bovine
serum albumin)) blocked with PBS, 0.1% Triton X-100, 5% BSA
for 1 h and incubated with Calcyclin (Santa Cruz biotechnology)
or GD2 (BD Pharmingen) antibody at 4uC overnight.
After washing with wash buffer, cells were incubated for 1 hour
with the appropriate secondary antibodies conjugated with Alexa
Fluor 488 or Alexa Fluor 568 (Invitrogen), washed with washing
buffer and mounted with vectashield mounting solution containing
DAPI for DNA counterstaining (Vector Laboratories).
For STOX1A-Halotag immunofluorescence, stable transfected
cells grown on coverslips were incubated with TMR-Halotag
ligand according the manufactures instructions (Promega). Cov-
erslips were fixed in 4% (PFA) paraformaldehyde for 15 min at
room temperature. After fixation, coverslips were washed with
washing buffer and mounted with vectashield mounting solution
containing DAPI for DNA counterstaining (Vector Laboratories).
Tau splicing Assay and ratio calculation
qRT-PCR was performed with RNA isolated from the stable
STOX1A transfected SK-N-SH and U-373 MG cell-lines and
transiently transfected SFRS7 and scrambled siRNA U-373 MG
cells on a Lightcycler 480 (Roche) using the SYBR Green master kit
and primers specific for the 3R (3R-forward: 59-GGAAGGTG-
CAAATAGTC-39, 3R-reversed: 59-CGACTGGACTCTGT-
CCTTGA-39) or 4R tau (4R-forward: 59-CGGGAAGGTGCA-
GATAATTAA-39, 4R-reversed: 59-GCCTAATGAGCCACAC-
TT GGAG-39) isoforms. Due to the high degree of homology
between 3R and 4R isoforms, the 3R 59-39 primer has 4 Locked
Nucleic Acid (LNA) modifications to ensure specificity. cDNA was
synthesized with the SuperScript III Reverse Transcriptase kit
(Invitrogen).Constructs containing the 3R or 4R tau isoforms with
known DNA concentrations were used for the generation of a
standard curve (concentrations for the constructs containing the 3R
isoform were 1022, 1023, 1024, 1025 and 1026 ng/ml and for the
constructs containing the 4R isoform 1023, 1024, 1025, 1026 and
1027 ng/ml). Experimental samples were measured and concentra-
tions calculated by comparison to the standard curve. Tau ratios
were calculated by dividing the mean 4R tau concentrations by the
mean 3R tau concentrations of the treated samples. The same was
done for the control treated samples. An unpaired t-test was used to
calculate significance between the treated 4R/3R tau ratio and
control treated 4R/3R tau ratio. Error bars represent 6 SEM.
Data analysis
For Real-time PCR data, a threshold cycle number, Ct, was
measured as the PCR cycle at which the amount of amplified target
reaches the threshold value. Quantification was determined by the
2-DDCt method as described in Applied Biosystems ‘‘Guide to
Performing Relative Quantitation of Gene Expression Using Real-
Figure 8. STOX1A effectuates endogenous total tau expression in U-373 MG cells. (A) Quantitative RT-PCR show a mean 2,33 fold (mean
DDCt is 21,22) increased mRNA expression for total tau. Bars are mean 6 SEM. * indicate P,0.05 (one sample t-test with theoretical mean 0). N = 4,
each sample was measured in triplicate. (B) Expression of endogenous total tau protein was determined with a total tau specific antibody by western
blot using total cell protein extracts obtained from STOX1A and MOCK transfected U-373 MG cells. An antibody specific for actin was used as a
loading control. Westernblot image is a representative of at least 3 independent experiments. (B, lower graph) Quantification of total tau protein was
performed using densitometry. The ratio number of obtained band intensities for STOX1A divided by actin was compared to the ratio number of
obtained band intensities for MOCK divided by actin for 3 independent experiments. A significant increase for the STOX1A ratio number was found
compared to the MOCK ratio number. P-values were calculated using two-tailed unpaired t-test, error bars represent 6 SEM, *** indicate P,0.001.
doi:10.1371/journal.pone.0021994.g008
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Time Quantitative PCR’’, Section VII, Relative Quantitation of
Gene Expression Experimental Design and Analysis http://www3.
appliedbiosystems.com/cms/groups/ mcb_support/documents/ge
neraldocuments/cms_042380.pdf). Statistical analysis of the ob-
tained data was carried out with the GraphPad Prism program.
For quantification of westernblots densitometry was used. Wester-
nblot pictures were analysed with the software ImageJ according to
the tutorial described on the website: http://lukemiller.org/index.
php/2010/11/analyzing-gels-and-western-blots-with-image-j/. Sta-
tistical analysis on the obtained density values was carried out with
Microsoft Excell and the GraphPad Prism program.
Supporting Information
Dataset S1 BED file as outputted by QuEST. The BED file
provided can be directly uploaded into the UCSC browser
(http://genome.ucsc.edu/) as a custom track. The human
assembly (Mar. 2006 NCBI36/hg 18) was selected as reference
genome. Custom tracks show genomic regions in blue and
potential binding peaks in red as calculated by QuEST.
(BED)
Dataset S2 Regions (BED file, Dataset S1) of functional
importance generated by CEAS as RefSeq genes. Can be
opened in Microsoft Excell.
(XLSX)
Text S1 Supplementary ChIP sequencing methods. Can
be opened in Microsoft Word.
(DOC)
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